胃经口内镜下肌切开术治疗难治性胃轻瘫:单中心前瞻性中期随访
该单中心前瞻性研究纳入52例药物难治性胃轻瘫患者,行G-POEM技术成功率100%,不良事件5.77%。术后1、6、12个月临床应答率分别为68%、58%、48%(P<.001、P<.001、P<.01),PAGI-SYM及SF-36多个维度显著改善,6个月4小时胃排空均值由36.5%降至10.2%(P<.001)。
要点
- G-POEM技术成功率100%,不良事件率5.77%且均内镜处理成功
- 1、6、12个月临床应答率分别为68%、58%、48%
- 6个月4小时胃排空均值由36.5%降至10.2%
核心结论
- G-POEM对难治性胃轻瘫安全可行,短期与中期整体症状、生活质量评分及医疗资源使用均有显著改善。
研究设计与样本
- 单中心前瞻性研究,连续纳入内科治疗失败的确诊胃轻瘫患者52例,中位年龄48岁(范围25-80岁),女性占88%。
- 术后1、3、6、12、24个月采用GCSI、PAGI-SYM、SF-36评估,术前及术后6个月行EGD、4小时闪烁显像及幽门EndoFLIP检查。
- 技术成功定义为完成全层幽门肌切开,临床应答定义为GCSI改善≥1分。
主要发现
- 技术成功率100%,52例中3例(5.77%)出现不良事件,均经内镜处理成功。
- 1、6、12个月临床应答率分别为68%、58%、48%(P<.001、P<.001、P<.01)。
- 按病因分层临床应答率:糖尿病性胃轻瘫64%(11/17)、术后胃轻瘫67%(6/9)、特发性胃轻瘫72%(13/18)。
- PAGI-SYM评分在1、3、6、12、24个月均显著改善,SF-36多个维度亦显著改善。
- 术后6个月4小时胃排空均值10.2%,较基线36.5%显著降低(P<.001);术后24个月内急诊就诊次数及住院天数显著减少。
关键数值与推荐
- 技术成功:能完成全层幽门肌切开。
- 临床应答:GCSI改善≥1分。
- 胃轻瘫表型:呕吐为主30例、消化不良为主16例、反流为主6例。
临床怎么用
- 对药物治疗失败的难治性胃轻瘫,G-POEM可作为安全可行的治疗选择。
- 术后应答随时间有所下降,需在1、3、6、12、24个月规律随访症状与生活质量。
- 糖尿病性、术后及特发性胃轻瘫均可考虑G-POEM,各病因应答率相近。
局限性
- 单中心前瞻性研究,样本量52例,结果外推需谨慎。
- 原文未报告对照组,无法与药物治疗或其他幽门干预直接比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Gastroparesis (GP) is a multifactorial disease associated with a large burden on the health care systems. Pyloric-directed therapies including gastric peroral endoscopic myotomy (G-POEM) can be effective in improving patient quality of life and symptom severity. We report on the safety and efficacy of G-POEM and its impact on the quality of life of patients managed at a large referral center. METHODS: Consecutive patients with confirmed GP referred for G-POEM due to failure of medical therapy were included. All patients were assessed at baseline and then at 1, 3, 6, and 12 and 24 months after G-POEM using validated symptom and quality of life instruments, including the Gastroparesis Cardinal Symptom Index (GCSI), Patient Assessment of Gastrointestinal Disorders Symptom Severity Index (PAGI-SYM), and 36-Item Short Form Survey (SF-36). Patients were evaluated before and 6 months after the procedure with EGD, 4-hour scintigraphy, and pyloric EndoFLIP. Technical success was defined as the ability to perform full-thickness pyloromyotomy. Clinical response was defined as an improvement of ≥1 point on GCSI. RESULTS: Fifty-two patients (median age, 48 years; range, 25-80 years, 88% female) underwent G-POEM between February 2018 and September 2020 for the following phenotypes: vomiting-predominant (n=30), dyspepsia-predominant (n=16), and regurgitation-predominant (n=6) GP. The technical success rate was 100%. Adverse events were noted in 3 of 52 patients (5.77%), and were all managed successfully endoscopically. Clinical response was achieved in 68%, 58%, and 48% of patients at 1-month, 6-month, and 12-month follow-up (P < .001, P < .001, and P < .01, respectively). When classified by the cause of GP, the clinical response rates were diabetic GP 64% (11 of 17), postsurgical GP 67% (6 of 9), and idiopathic GP 72% (13 of 18). A statistically significant improvement in PAGI-SYM scores was observed at 1, 3, 6, 12, and 24 months, in addition to significant improvement in several domains of SF-36. Mean 4-hour gastric emptying was reduced 6 months after G-POEM (10.2%) compared with baseline (36.5%, P < .001). We report a significant reduction in the number of emergency department visits and days spent in the hospital up to 24 months after G-POEM. CONCLUSIONS: G-POEM appears to be a safe and feasible treatment alternative for refractory GP with significant short-term and mid-term improvements in overall symptoms, quality of life scores, and health care utilization.
引用
- Gregor L, Wo J, DeWitt J, et al. Gastric peroral endoscopic myotomy for the treatment of refractory gastroparesis: a prospective single-center experience with mid-term follow-up (with video). Gastrointest Endosc. 2020. PMID: 33373646. doi:10.1016/j.gie.2020.12.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。